Evaluation of Antipsychotic Drug Use in Paranoid Schizophrenia Patients
Abstract
One of schizophrenia’s treatment is pharmacological therapy using antipsychotic. This study aims to determine the demographic description (age, gender and length of stay), determine the pattern of antipsychotic drug use, determine the level of appropriateness of antipsychotic drug therapy based on the right patient, the right indication, the right drug, the right dose, and the right interval of administration based on the Rational Drug Use Module and Drug Information Handbook 27th Edition and determine the reduction in the final symptoms of schizophrenia patients after receiving antipsychotic drug therapy at the Inpatient Installation of dr. Soeharto Heerdjan Mental Hospital Jakarta for the period January - June 2023. The research method used is descriptive, with cross sectional design. Data collected retrospectively and using purposive sampling techniques. The study analyzed 95 prescription samples, showing that schizophrenia is more experience in in the range of 26-35 years old (44,21%) and in men (67.37%). The most common antipsychotic use was the atypical combination antipsychotic with the percentage of 37.5%. The single atypical antipsychotic most commonly prescribed is atypical antipsychotic with the percentage of 57.15%. The results showed that the appropriateness of the use of antipsychotics in correct patient is in 100%, correct indication is in 100%, correct drug is in 100%, correct dose is in 97.89% and the exact dosing interval of drug is in 92.63%. There was a decrease in schizophrenia symptoms in patients after undergoing hospitalization as seen from the decrease in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) scores with an average percentage decrease of 48%. This difference is clinically effective because the decrease exceeds 19– 28 %.
References
A. R. Fadilla, & R. M. Puspitasari. (2016). Evaluasi Ketepatan Penggunaan Antipsikotik pada Pasien Skizofrenia Rawat Inap. Sainstech Farma Vol 9 No 1. ISSN: 2086 – 7816. 9(1), 41–45.
America Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, DSM-IV-TR. Arlington, VA: American Psychiatric Association
Apriliya, T. & Puspitasari, I. (2023). Review Artikel: Adverse Drug Events Aripiprazole Pada Pasien Dengan Gejala Psikosis. Jurnal Farmaka Vol 21 No. 1. 50 – 63.
Balqis, K., Priastomo, & M., Ramadhan, A. (2020) Evaluasi Ketepatan Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap Rumah Sakit Jiwa Daerah Atma Husada Mahakam Samarinda. Proceeding of Mulawarman Pharmaceuticals Conferences. e- ISSN: 2614- 4778. 14–21.
Dania H,, Faridah I. N., Rahma K. F., Abdulah R., Barliana M. I., & Perwitasari D. A. (2019). Hubungan Pemberian Terapi Antipsikotik terhadap Kejadian Efek Samping Sindrom Ekstrapiramidal pada Pasien Rawat Jalan di Salah Satu Rumah Sakit di Bantul Yogyakarta. Jurnal Farmasi Klinik Indonesia, 8(1): 19-30.
Endriyani S,, Marta P., & Martini, S. (2023). The Influence of De-Escalation Techniques on Reducing Anger Responses in Drug Clients. Formosa Journal of Science and Technology. Vol.2, No.6, 2023: 1465- 1480.
Faqih, M., Hendera, Hartanto, D. (2021). Evaluasi Pengobatan Antipsikotik Pada Pasien Skizofrenia Di Rumah Sakit Jiwa Sambang Lihum. Journal of Current Pharmaceutical Sciences. 5(1), 439-446.
Kementerian Kesehatan Republik Indonesia. (2011). Modul Penggunaan Obat Rasional. Direktur Bina Pelayanan Kefarmasian. Jakarta.
Kementerian Kesehatan Republik Indonesia. (2016). Pedoman Nasional Pelayanan Kedokteran Jiwa. Kementerian Kesehatan Republik Indonesia. Jakarta.
Kementerian Kesehatan Republik Indonesia. (2018). Hasil Riset Kesehatan Dasar (Riskesdas) 2018. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia. Jakarta.
Kementerian Kesehatan Republik Indonesia. (2020). Rencana Aksi Kegiatan 2020 – 2024. Direktorat P2 Masalah Kesehatan Jiwa Dan Napza. Jakarta.
Maylani, R. Y., Fadraersada, J., & Ramadhan, A. M. (2018). Studi Pemberian Antipsikotik terhadap Beberapa Jenis Skizofrenia Di RSJD Atma Husada Mahakam Samarinda. Proceeding of Mulawarman Pharmaceuticals Conferences, 8(1), 267–275.
Meilina, N. A., Cahaya, N., & Putra, A. M. P. (2022). Analisis Trend Peresepan Golongan Antipsikotika Tipikal dan Atipikal di Tiga Puskesmas di Kota Banjarmasin Periode 2019- 2021. Jurnal Sains dan Kesehatan, 4(4), 393-400.
Musdalifah, W., Susanti, R., & Robiyanto. (2019). Evaluasi Penggunaan Obat Triheksifenidil sebagai Terapi Adjuvan pada Pasien Skizofrenia di Instalasi Rawat Inap Rumah Sakit Jiwa Daerah Sungai Bangkong Pontianak. Jurnal Mahasiswa Farmasi Fakultas Kedokteran UNTAN, 4(1).
Nasikha, Rizky. (2020). Analisis Efektivitas Penggunaan Obat Antipsikotik Tipikal dan Atipikal Pada Pasien Skizofrenia. UIN Syarif Hidayatullah, Jakarta.
Ningnurani, Romas & Widiantoro. (2022). Studi Kasus Penderita Skizofrenia Paranoid. Jurnal Psikologi, Vol. 18, No 1, 25-29
Noor, Nasrudin., & Hanief, Nur. (2021). Gambaran Penggunaan Obat Antipsikotik Pada Pasien Skizofrenia di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Periode Januari – Juni 2017. Yarsi Journal of Pharmacology Vol 2 No 1. e-ISSN: 2716-4578. 2(1), 13–22.
Notoatmodjo, S. (2012). Metodologi Penelitian Kesehatan. Rhineka Cipta. Jakarta.
Padmasari, S. dan Sugiyono. (2019). Evaluasi Rasionalitas Penggunaan Obat Antipsikotik Pada Pasien Skizofrenia Di Instalasi Rawat Inap Rumah Sakit Jiwa Grhasia Yogyakarta Tahun 2017. Jurnal Act Holis Pharm. 1 (1): 25-32.
Paramitha, R., Endang, E., dan Kartika, M. (2018). Analisis Rasionalitas Penggunaan Antipsikotik Pada Pasien Skizofrenia Di Instalasi Rawat Inap RSJD Atma Husada Mahakam Samarinda Tahun 2016. Pharmacon: Jurnal Farmasi Indonesia Vol. 15 No. 1. ISSN 1411-4283. 19-28.
Patel, K., Cherian, J., Atkinson, D. (2014). Schizophrenia: Overview and Treatment Options, Pharmacy and Therapeutics Journal (39) 9, 638 – 640.
Purwandityo, A. G., Febrianti, Y., & Sari, C. P. (2018). Pengaruh Antipsikotik terhadap Penurunan Skor The Positive and Negative Syndrome Scale- Excited Component. Jurnal Farmasi Klinik Indonesia, 7(1), 19–29.
Rissa, MM, Darmawan, E., & Siwinarni, A. (2020). Profil Penggunaan Obat Kombinasi Risperidone- Clozapine dan Risperidone dengan Antipsikotik Lain pada Pasien Gangguan Mental Psikotik di Rumah Sakit Jiwa Grhasia Yogyakarta: Jurnal Surya Medika (JSM) , 5 (2), 131–138.
Saharuddin, Ikawati, Z., & Kristanto. (2021). Perbandingan Efektivitas Regimen Terapi Antipsikotik Pasien Schizophrenia di RSJ Dr.Ernaldi Bahar Palembang. Majalah Farmaseutik, 17(2), 206–216.
Salwan, J., Woldu, H., Rosen, A., & Katz, C. L. (2013). Application for Inclusion to The 19th Expert Committee on The Selection and Use of Essential Medicines: Risperidone. World Health Organization.
Syarif, I., Nursiah, A & Idris. (2020) Faktor risiko kejadian relaps pada penderita skizofrenia paranoid di RSKD Provinsi Sulawesi Selatan. Jurnal Syntax Idea, Vol. 2 No.11. 2(11). 851–855.
Sona, A., Hasni, D., Annisa, M., & Heppy, F. (2020). Identifikasi Keluhan Peningkatan Berat Badan Subjektif pada Pasien Skizofrenia yang Mendapat Terapi Antipsikotik di RSJ HB. Saanin Padang. Jurnal Kedokteran dan Kesehatan Vol 16 No. 1. 6–11.
Tjay, H.T., dan Rahardja, K. (2015). Obat-Obat Penting, Edisi VII, PT.Gramedia, Jakarta
Videbeck, Sheila L. (2020) Psychiatric Mental Health Nursing 8th Edition. Wolters Kluwer Health, China.
Zahnia, Siti, & Sumekar, Dyah Wulan. (2016) Kajian Epidemiologis Skizofrenia. Jurnal Majority, 5(4), 160-166
Copyright (c) 2025 Indonesian Journal of Global Health Research

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.